Recurrent peritoneal serous carcinoma that was unmanageable with paclitaxel-carboplatin therapy responded to autologous formalin-fixed tumor vaccine.
Paclitaxel-carboplatin therapy (TC) usually controls primary peritoneal serous carcinoma (PPSC) but not recurrent disease. In this case, PPSC recurred after three courses of TC, responded dramatically to additional autologous formalin-fixed tumor vaccine (AFTV), and resulted in prolonged, progression-free survival without visible lesions detected by positron emission tomography-computed tomography.
Jui-Tung Chen Clinic Akasaka 2-13-5-B1F, Minato-ku, Tokyo, 107-0052, Japan.
Jui-Tung
JT
Chen
Cell-Medicine, Inc. Sengen 2-1-6-C-B-1, Tsukuba Science City, Ibaraki, 305-0047, Japan.
Tadao
T
Ohno
Autologous formalin-fixed tumor vaccine; chemoresistance; peritoneal serous carcinoma